Physician profile
Amit Tibrewala
NPI 1720275233
$6,698.36
in general payments reported to CMS, 2019-2025
33 companies · $512 in 2025
The $512 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,623 · 2020: $631 · 2021: $1,214 · 2022: $488 · 2023: $1,226 · 2024: $1,005 · 2025: $512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,743.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $897.72 | 2019-2024 | Lifevest |
| Amgen INC. | $722.36 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $679.40 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $562.67 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $500.48 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $419.00 | 2019-2025 | |
| Esperion Therapeutics, INC. | $381.64 | 2021-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $340.00 | 2021-2025 | Verquvo |
| Boston Scientific Corporation | $230.92 | 2019-2023 | Watchman Flx, Watchman Access System |
| Pfizer INC. | $166.50 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $154.09 | 2019-2021 | |
| Heartflow, INC. | $145.97 | 2023-2025 | Ffrct |
| Medtronic Vascular, INC. | $142.70 | 2019 | |
| Medtronic, INC. | $141.35 | 2023 | Micra |
| Janssen Scientific Affairs, LLC | $132.80 | 2024 | Xarelto |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $128.60 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Astellas Pharma US INC | $117.72 | 2019 | |
| Nuwellis, INC. | $115.62 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $115.44 | 2021-2024 | Wainua |
| Sanofi-Aventis U.S. LLC | $93.82 | 2019-2021 | |
| Amarin Pharma, INC. | $87.24 | 2019-2021 | |
| Kestra Medical Technology Services, INC. | $62.24 | 2024 | Assure Wcd |
| Kiniksa Pharmaceuticals International, Plc | $55.82 | 2024 | Arcalyst |
| Edwards Lifesciences Corporation | $51.97 | 2019-2020 | |
| Lantheus Medical Imaging, INC. | $42.99 | 2021-2024 | |
| Kiniksa Pharmaceuticals, LTD. | $38.77 | 2023 | Arcalyst |
| Cvrx, INC. | $36.33 | 2023 | Barostim Neo System |
| Chiesi USA, INC. | $33.51 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.61 | 2021-2025 | |
| Abbott Laboratories | $25.00 | 2021 | |
| Novo Nordisk INC | $19.84 | 2022 | |
| Amryt Pharma Holdings LTD | $13.90 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Tibrewala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.